On this episode of Stock Movers:
- Netflix (NFLX) shares rise after the company reached an amended, all-cash agreement to buy Warner Bros. Discovery Inc.’s studio and streaming business. The changes are designed to expedite a sale and address claims by Paramount that its cash tender offer is superior.
- Applovin (APP) shares slump underperforming tech peers after a negative research report by CapitalWatch. The stock was also weighed down by a broader tech selloff amid rising geopolitical tensions.
- Intel (INTC) share rise after the company was was upgraded to hold from reduce at HSBC, which noted that agentic artificial intelligence is driving upside to server CPU demand. Shares up 0.2% premarket.

On this episode of Stock Movers: - Netflix (NFLX) shares rise after the company reached an amended, all-cash agreement to buy Warner Bros. Discovery Inc.&rsquo;s studio and streaming business. The changes are designed to expedite a sale and address claims by Paramount that its cash tender offer is superior. - Applovin (APP) shares slump underperforming tech peers after a negative research report by CapitalWatch. The stock was also weighed down by a broader tech selloff amid rising geopolitical tensions. - Intel (INTC) share rise after the company was was upgraded to hold from reduce at HSBC, which noted that agentic artificial intelligence is driving upside to server CPU demand. Shares up 0.2% premarket.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Netflix Rises, Applovin Slumps, Intel Rises on Ratings Upgrade

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/b1c07110-7486-4a1a-863e-b3d800fe6b7d/transcript

On this episode of Stock Movers:
- 3M (MMM) drops after the company said its' profit outlook fell narrowly short of Wall Street’s expectations for this year. Adjusted earnings will be $8.50 to $8.70 a share in 2026, the manufacturer said Tuesday in a statement. The midpoint was slightly below the $8.64 average of analyst estimates compiled by Bloomberg. Adjusted sales will climb about 4%, the company said.
- Strategy (MSTR) shares fall after the company acquired almost $2.13 billion in Bitcoin over the previous eight days, marking the digital asset treasury company’s largest purchase of the original cryptocurrency since July.
- ImmunityBio (IBRX) shares rise after the drug developer said it held a Type B End-of-Phase meeting with the US FDA regarding its supplemental application for its drug to treat bladder cancer. The FDA recommended that the company provide additional information to support a potential resubmission of the supplemental Biologics License Application (sBLA) for Anktiva in combination with Bacillus Calmette-Guérin (BCG.)

On this episode of Stock Movers: - 3M (MMM) drops after the company said its' profit outlook fell narrowly short of Wall Street&rsquo;s expectations for this year. Adjusted earnings will be $8.50 to $8.70 a share in 2026, the manufacturer said Tuesday in a statement. The midpoint was slightly below the $8.64 average of analyst estimates compiled by Bloomberg. Adjusted sales will climb about 4%, the company said. - Strategy (MSTR) shares fall after the company acquired almost $2.13 billion in Bitcoin over the previous eight days, marking the digital asset treasury company&rsquo;s largest purchase of the original cryptocurrency since July. - ImmunityBio (IBRX) shares rise after the drug developer said it held a Type B End-of-Phase meeting with the US FDA regarding its supplemental application for its drug to treat bladder cancer. The FDA recommended that the company provide additional information to support a potential resubmission of the supplemental Biologics License Application (sBLA) for Anktiva in combination with Bacillus Calmette-Gu&eacute;rin (BCG.)

3M Drops, Strategy Falls, ImmunityBio Drops After FDA Meeting Update  On this episode of Stock Movers:

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/30f763ee-6452-4b3a-afb4-b3d8010b3b7d/transcript

On this episode of Stock Movers:
- 3M (MMM) shares fall after the industrial company gave an outlook for this year’s adjusted earnings per share with a midpoint below what analysts expected. JPMorgan says the company had a “mixed” end to 2025, with adjusted organic growth missing their estimate.
- Netflix (NFLX) reached an amended, all-cash agreement to buy Warner Bros. Discovery Inc.’s studio and streaming business as it battles Paramount Skydance Corp. to acquire one of Hollywood’s most iconic entertainment companies. Netflix, which previously agreed to pay $27.75 a share in cash and stock for the Warner assets, will pay the full amount in cash, according to a filing confirming an earlier Bloomberg News report on the revised terms. Warner Bros. plans to call a special meeting of shareholders to approve the deal. Netflix said stockholders should be able to vote on the transaction by April.
- GSK (GSK) agreed to buy Rapt Therapeutics (RAPT), a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.The UK drug company will pay $58 a share, equivalent to an equity value of $2.2 billion, according to a statement Tuesday. The price represents a premium of 65% compared with Rapt Therapeutics’ closing price of $35.10 on Monday.

On this episode of Stock Movers: - 3M (MMM) shares fall after the industrial company gave an outlook for this year&rsquo;s adjusted earnings per share with a midpoint below what analysts expected. JPMorgan says the company had a &ldquo;mixed&rdquo; end to 2025, with adjusted organic growth missing their estimate. - Netflix (NFLX) reached an amended, all-cash agreement to buy Warner Bros. Discovery Inc.&rsquo;s studio and streaming business as it battles Paramount Skydance Corp. to acquire one of Hollywood&rsquo;s most iconic entertainment companies. Netflix, which previously agreed to pay $27.75 a share in cash and stock for the Warner assets, will pay the full amount in cash, according to a filing confirming an earlier Bloomberg News report on the revised terms. Warner Bros. plans to call a special meeting of shareholders to approve the deal. Netflix said stockholders should be able to vote on the transaction by April. - GSK (GSK) agreed to buy Rapt Therapeutics (RAPT), a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.The UK drug company will pay $58 a share, equivalent to an equity value of $2.2 billion, according to a statement Tuesday. The price represents a premium of 65% compared with Rapt Therapeutics&rsquo; closing price of $35.10 on Monday.

3M Profit Outlook Light; Netflix Amends Warner Bros. Deal; GSK to Buy Rapt Therapeutics

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/ce612af8-96dc-47b7-bf90-b3d800e9bd93/transcript

On this episode of Stock Movers:
- GSK (GSK) agreed to buy Rapt Therapeutics (RAPT), a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion. The UK drug company will pay $58 a share, equivalent to an equity value of $2.2 billion, according to a statement Tuesday. The price represents a premium of 65% compared with Rapt Therapeutics’ closing price of $35.10 on Monday.
- 3M (MMM) expects profit and sales to expand this year, signaling the company’s push to prioritize higher-growth markets and accelerate the introduction of new products will continue to lift its results.Adjusted earnings will be $8.50 to $8.70 a share in 2026, the maker of Post-it notes, roofing granules and electronics materials said Tuesday in a statement that also revealed better-than-expected quarterly results. Analysts had expected $8.64 on average, according to the average of estimates compiled by Bloomberg. Adjusted sales will climb about 4%, the company said.
- Homebuilder D.R. Horton (DHI) missed analysts’ estimates for quarterly home orders even as mortgage rates slid. The company reported 18,300 signed contracts for the three months through December, up 3% from a year earlier, according to a statement Tuesday. Analysts were expecting 18,653, the average in a survey compiled by Bloomberg.

On this episode of Stock Movers: - GSK (GSK) agreed to buy Rapt Therapeutics (RAPT), a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion. The UK drug company will pay $58 a share, equivalent to an equity value of $2.2 billion, according to a statement Tuesday. The price represents a premium of 65% compared with Rapt Therapeutics&rsquo; closing price of $35.10 on Monday. - 3M (MMM) expects profit and sales to expand this year, signaling the company&rsquo;s push to prioritize higher-growth markets and accelerate the introduction of new products will continue to lift its results.Adjusted earnings will be $8.50 to $8.70 a share in 2026, the maker of Post-it notes, roofing granules and electronics materials said Tuesday in a statement that also revealed better-than-expected quarterly results. Analysts had expected $8.64 on average, according to the average of estimates compiled by Bloomberg. Adjusted sales will climb about 4%, the company said. - Homebuilder D.R. Horton (DHI) missed analysts&rsquo; estimates for quarterly home orders even as mortgage rates slid. The company reported 18,300 signed contracts for the three months through December, up 3% from a year earlier, according to a statement Tuesday. Analysts were expecting 18,653, the average in a survey compiled by Bloomberg.

Stock Movers: Rapt, 3M, D.R. Horton (Podcast)

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/49f15698-badd-4e4c-979b-b3d800c6179c/transcript

Netflix Rises, Applovin Slumps, Intel Rises on Ratings Upgrade

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips